Screener
Madrigal Pharmaceuticals, Inc. MDGL Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Rebates, returns and other revenue related reserves | $152,272 | $90,504 |
| Clinical study, manufacturing and drug supply | 29,890 | 26,907 |
| Compensation and benefits | 46,124 | 69,211 |
| Selling, general and administrative | 57,911 | 40,026 |
| Other | 52,459 | 33,744 |
| Total accrued liabilities | $338,656 | $260,392 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s accrued expenses?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported accrued expenses of $46.12M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s accrued expenses increased by 66.6% year-over-year, from $27.69M to $46.12M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s accrued expenses has grown at a 41.9% compound annual growth rate (CAGR), from $45.22M to $260.39M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude